Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients
30 nov. 2022 07h00 HE
|
Aridis Pharmaceuticals, Inc.
Los Gatos, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective...
Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases
22 nov. 2022 09h10 HE
|
Aridis Pharmaceuticals, Inc.
The Company’s superiority Phase 3 ‘ASAP-1' study of AR-301 monoclonal antibody in S. aureus pneumonia and the pending data readout will be a focus of the KOL event Los Gatos, Calif., Nov. 22, 2022 ...
Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update
21 nov. 2022 18h30 HE
|
Aridis Pharmaceuticals, Inc.
Top-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP expected in December of this year LOS GATOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aridis...